Stephanie Halene, MD, PhD

Assistant Professor of Medicine (Hematology)

Patient Care

Accepts new patients? No
Patient Type: Adult
Referrals: From physicians only

Patient Care Organizations

Cancer Center, Yale: Hematology Program

Hematology

Yale Medical Group

Board Certifications

  • Hematology (Internal Medicine) AB of Internal Medicine (2006)

Clinical Trials

Conditions Study Title
Myeloid and Monocytic Leukemia E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, other (E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Unknown Sites Specimen Repository for Hematologic Diseases
Leukemia, other A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease
Myeloid and Monocytic Leukemia A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Myeloid and Monocytic Leukemia A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory AML Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Randomized, Double-Blind Phase 1B/2 Study of PF-04449913 in Combination with Azacitidine in Patients with Previously Untreated Intermediate-2 or High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts and Multi-Lineage Dysplasia, or Chronic Myelomonocytic Leukemia
Myeloid and Monocytic Leukemia A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Edit this profile

Contact Info

Stephanie Halene, MD, PhD
Patient Care Location
Yale-New Haven Hospital
20 York Street

New Haven, CT 06510
Mailing Address
300 George St. 786
New Haven, CT 06511